AUTOANTIBODIES AND SYSTEMIC SCLEROSIS

Launched by IRCCS OSPEDALE SAN RAFFAELE · Jul 9, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a condition called Systemic Sclerosis (SSc), which is an autoimmune disease that can cause skin and internal organ changes. The research aims to better understand how specific antibodies in the blood affect the disease and how a medication called Efgartigimod might help. The trial will use advanced laboratory tests to look at how cells behave when exposed to these antibodies and the potential benefits of the treatment. Researchers will investigate whether Efgartigimod can prevent or improve changes in blood vessel and cell function related to SSc.

To participate in this study, individuals must have positive autoantibodies related to SSc and be between the ages of 65 and 92. Unfortunately, pregnant individuals cannot join the trial. While the study is not yet recruiting participants, those who take part can expect to contribute to important research that may lead to new insights and treatment approaches for SSc. As the study progresses, researchers hope to uncover valuable information that could guide future therapies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • positivity of autoantibodies
• Exclusion Criteria:
• • pregnant